266,723 Shares in Solventum Co. (NYSE:SOLV) Bought by Ananym Capital Management LP

Ananym Capital Management LP bought a new stake in Solventum Co. (NYSE:SOLV - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 266,723 shares of the company's stock, valued at approximately $17,620,000. Solventum accounts for about 9.7% of Ananym Capital Management LP's investment portfolio, making the stock its 6th biggest holding. Ananym Capital Management LP owned about 0.15% of Solventum as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of SOLV. Clarity Asset Management Inc. acquired a new stake in Solventum in the fourth quarter valued at $25,000. Stonebridge Financial Group LLC acquired a new stake in Solventum in the fourth quarter valued at $26,000. Raiffeisen Bank International AG acquired a new stake in Solventum in the fourth quarter valued at $29,000. Crews Bank & Trust acquired a new stake in Solventum in the fourth quarter valued at $32,000. Finally, Synergy Asset Management LLC acquired a new stake in Solventum in the fourth quarter valued at $35,000.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Piper Sandler raised shares of Solventum from a "neutral" rating to an "overweight" rating and upped their price target for the company from $78.00 to $87.00 in a report on Monday, May 19th. Mizuho increased their target price on shares of Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a report on Monday, March 3rd. Bank of America upped their price target on shares of Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 26th. The Goldman Sachs Group increased their target price on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research report on Monday, March 3rd. Finally, Wells Fargo & Company raised their price objective on shares of Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a research report on Friday, February 28th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $80.29.

Solventum Stock Performance

SOLV stock traded up $1.51 during midday trading on Tuesday, hitting $72.32. 255,267 shares of the company traded hands, compared to its average volume of 1,242,880. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $85.92. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The business has a 50 day simple moving average of $69.60 and a 200-day simple moving average of $71.25. The stock has a market capitalization of $12.51 billion and a price-to-earnings ratio of 33.48.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.15. The company had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.02 billion. The company's revenue was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.08 EPS. As a group, equities research analysts predict that Solventum Co. will post 6.58 earnings per share for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.